title: Prevention of fibrinolytic shut-down after major surgery by intramuscular stanozolol.
abstract: The effects of a single pre-operative intramuscular injection of the anabolic steroid stanozolol (Stromba, 50 mg) on fibrinolysis and blood viscosity were evaluated in 14 patients at high risk of post-operative deep venous thrombosis. A control group of 13 high risk patients was also studied. The mean level of plasma plasminogen activator activity decreased significantly (p < 0.05) on the first post-operative day in the control group. In contrast, the fibrinolytic activator activity showed a non-significant rise on the first postoperative day in the stanozolol treated group. The difference in plasminogen activator levels on the first post-operative day between treated and control groups was significant (p < 0.05). Plasma plasminogen levels on the first post-operative day increased from preoperative levels in the treated group (p < 0.01), but not in the control group. The prevention of fibrinolytic shut-down and stimulation of plasminogen levels by a single pre-operative injection suggests that trials of intramuscular stanozolol in the prevention of postoperative deep venous thrombosis are indicated.
authors.affiliation: University Department of Medicine, Glasgow Royal Infirmary.
authors.forename: S L
authors.initials: SL
authors.lastname: Blamey
authors.forename: B M
authors.initials: BM
authors.lastname: McArdle
authors.forename: P
authors.initials: P
authors.lastname: Burns
authors.forename: G D
authors.initials: GD
authors.lastname: Lowe
authors.forename: C D
authors.initials: CD
authors.lastname: Forbes
authors.forename: D C
authors.initials: DC
authors.lastname: Carter
authors.forename: C R
authors.initials: CR
authors.lastname: Prentice
mesh_terms: D000005:Abdomen / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D045930:Anabolic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000728:Androgens / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D001809:Blood Viscosity / Q000187:drug effects; D016022:Case-Control Studies; D017558:Elective Surgical Procedures; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007273:Injections, Intramuscular; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D010960:Plasminogen Activators / Q000097:blood; D011183:Postoperative Complications / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D011300:Preoperative Care; D013197:Stanozolol / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*
chemical_list: D045930:Anabolic Agents; D000728:Androgens; D015415:Biomarkers; D013197:Stanozolol; D005340:Fibrinogen; D010958:Plasminogen; D010960:Plasminogen Activators